Tra­con inks deal with Am­brx to de­vel­op can­cer drug in Chi­na; Roche wins con­sec­u­tive ap­provals in EU and US

→ Two San Diego com­pa­nies have inked a li­cens­ing deal to de­vel­op a can­cer drug in Chi­na and Tai­wan. Am­brx gets ex­clu­sive rights to de­vel­op and com­mer­cial­ize Tra­con Phar­ma­ceu­ti­cals $TCON lead prod­uct TRC105 in all in­di­ca­tions ex­cept oph­thal­mol­o­gy (those rights are al­ready held by San­ten Phar­ma­ceu­ti­cal). The drug caro­tux­imab, a pro­pri­etary en­doglin an­ti­body, is cur­rent­ly be­ing test­ed by Tra­con in an­giosar­co­ma, RCC, HCC, GTN, lung and breast can­cer. Tra­con will re­ceive an up­front pay­ment of $3 mil­lion, and is el­i­gi­ble to re­ceive de­vel­op­ment and reg­u­la­to­ry mile­stones of up to $10.5 mil­lion and com­mer­cial sales mile­stones of up to $130 mil­lion. Am­brx in­tends to file an ini­tial CTA with the Chi­nese Food and Drug Ad­min­is­tra­tion (CF­DA) in 2018.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER